Jobs / United States / Astrazeneca Pharmaceuticals Lp
Director, Strategic Site Partnerships – Cell Therapy
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
Introduction to Role As Director, Strategic Site Partnerships – Cell Therapy, you will serve as the accountable leader for AstraZeneca’s end-to-end relationship with a defined portfolio of priority cell therapy sites. You will combine strategic alliance leadership with clinical and operational expertise to translate enterprise priorities into integrated site strategies, coordinated action, stronger portfolio execution, and lasting partnerships spanning scientific collaboration, early clinical development, and launch readiness. As AstraZeneca’s strategic point of contact for select Cell Therapy Strategic Partnership Sites, you will align the Alliance Joint Steering Committee (JSC), investigators, site leadership, and AstraZeneca’s cross-functional partnership team around shared priorities, clear accountabilities, and measurable outcomes. You will help remove barriers across the patient and site journey, enable high-quality clinical trial delivery, and ensure site insights inform decisions across the broader cell therapy portfolio. Why This Role This is an opportunity to shape high-impact partnerships at the forefront of cell therapy and oncology. You will represent the breadth of AstraZeneca’s cell therapy portfolio at the site level, strengthen collaboration with leading treatment centers, and help improve activation timelines, enrollment, protocol adherence, patient access, and site experience. By creating a continuous feedback loop between strategic sites and global teams, you will identify recurring barriers early and help convert site-level insights into scalable solutions. Your leadership will support clinical development today while preparing strategic sites for future programs, new indications, and clinical-to-commercial transitions. Accountabilities Strategic Site Ownership and Governance • Serve as Alliance Manager for the Cell Therapy Strategic Partnership Joint Steering Committee. • Act as the primary AstraZeneca relationship owner and enterprise-level escalation point for assigned strategic sites across the cell therapy portfolio. • Partner with the Senior Director, Cell Therapy Partnership and Strategy and the Strategic Partnership Joint Steering Committee to develop and maintain a multi-year site partnership plan. • Integrate clinical development priorities, site capabilities, mutual value, risks, and readiness for future programs into a cohesive site strategy. • Lead joint governance and executive-level partnership reviews with clear agendas, decisions, actions, owners, and follow-through. • Ensure required internal governance approvals are obtained. • Build trusted relationships with site leadership, investigators, cell therapy program leaders, research operations, pharmacy, apheresis, inpatient and outpatient care teams, and administrative stakeholders. • Maintain a comprehensive view of AstraZeneca’s portfolio and engagement at each site. • Coordinate the timing and sequencing of site interactions to reduce duplication, conflicting requests, and relationship fatigue. • Lead the cross-functional site partnership team, mobilize the appropriate AstraZeneca expertise, clarify accountabilities, and drive coordinated execution. Portfolio Execution and Performance • Establish an integrated site performance plan across active and planned studies, with clear priorities, performance measures, and proposed mitigations. • Support improvements in site activation, enrollment, patient flow, retention, protocol adherence, patient access, site experience, and issue resolution. • Partner with Clinical Development, Study Management, Site Management and Monitoring, Patient Operations, Supply and Logistics, Country Operations, and other functions to identify root causes and accelerate the resolution of cross-study bar